22
nanotimes
Companies
Facts
D. Pires, J. L. Hedrick, A. De Silva, J. Frommer, B. Gots- mann, H. Wolf, M. Despont, U. Duerig and A. W. Knoll: Nanoscale 3D Patterning of Molecular Resists by Scanning Probes, In: Science Express, April 22, 2010, DOI:10.1126/ science. 1187851:
http://dx.doi.org/10.1126/science. 1187851
A. Knoll, D. Pires, O. Coulembier, P. Dubois, J. L. Hedrick, J. Frommer and U. Duerig: Probe-based 3-D Nanolitho- graphy Using Self-Amplified Depolymerization Polymers; In: Advanced Materials AOP, April 23, 2010, DOI:10.1002/ adma. 200904386:
http://dx.doi.org/10.1002/adma.200904386 http://www.ibm.com
I
llumina, Inc. (NASDAQ: ILMN) announced the launch of its VeraCode ADME Core Panel designed
to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most comple- te representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List. The panel contains 184 biomarkers in 34 genes, with the highest coverage of the PharmADME Core List. Using a highly specific and streamlined chemistry, DNA can be genotyped within 8 hours with less than 2.5 hours of hands-on time, enabling researchers to complete studies faster than ever before.
Furthermore, the Company announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the company‘s BeadX- press system for multiplex genetic analysis. Accor- ding to the FDA‘s indications of use, the BeadXpress system – consisting of Illumina‘s BeadXpress Reader
Advertisement
10-04 :: April 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87